Part III | Chapter 11 226 43. Kontaxis C, de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, den Hartogh MD, van der Voort van Zyp JRN, et al. Delivered dose quantification in prostate radiotherapy using online 3D cine imaging and treatment log files on a combined 1.5 T magnetic resonance imaging and linear accelerator system. Phys Imaging Radiat Oncol 2020;15. 44. De Roover R, Hansen R, Crijns W, Muurholm CG, Poels K, Skouboe S, et al. Dosimetric impact of intrafraction prostate rotation and accuracy of gating, multi-leaf collimator tracking and couch tracking to manage rotation: An end-to-end validation using volumetric film measurements. Radiother Oncol 2021;156:10–8. 45. Uijtewaal P, Borman PTS, Woodhead PL, Hackett SL, Raaymakers BW, Fast MF. Dosimetric evaluation of MRI-guided multi-leaf collimator tracking and trailing for lung stereotactic body radiation therapy. Med Phys 2021;48:1520–32. 46. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011;6:3. 47. King CR, Brooks JD, Gill H, Presti JC. Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer. Int J Radiat Oncol 2012;82:877–82. 48. Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 2015;16:274–83. 49. Kishan AU, King CR. Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. Semin Radiat Oncol 2017;27:268–78. 50. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20:1531–43. 51. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, noninferiority, phase 3 trial. Lancet 2019;394:385–95. 52. Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results. Int J Radiat Oncol Biol Phys 2019;105:1086–94. 53. Tetar SU, Bruynzeel AME, Oei SS, Senan S, Fraikin T, Slotman BJ, et al. Magnetic Resonance-guided Stereotactic Radiotherapy for Localised Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol 2021;4:628–34. 54. Murray J, Tree AC. Prostate cancer – Advantages and disadvantages of MR-guided RT. Clin Transl Radiat Oncol 2019;18:68–73. 55. Verkooijen HM, Kerkmeijer LGW, Fuller CD, Huddart R, Faivre-Finn C, Verheij M, et al. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol 2017;7:1–7. 56. Ma TM, Lamb JM, Casado M, Wang X, Basehart TV, Yang Y, et al. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. BMC Cancer 2021;21:538. 57. Kerkmeijer LGW, Valentini V, Fuller CD, Slotman BJ. Editorial: Online Adaptive MR-Guided Radiotherapy. Front Oncol 2021;11. 58. Ward JF, Pagliaro LC, Pisters LL. Salvage Therapy for Radiorecurrent Prostate Cancer. Curr Probl Cancer 2008;32:242–71. 59. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically Significant Prostate Cancer Local Recurrence After Radiation Therapy Occurs at the Site of Primary Tumor: Magnetic Resonance Imaging and Step-Section Pathology Evidence. Int J Radiat Oncol Biol Phys 2007;69:62–9. 60. Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 2015;67:1009–16. 61. Spratt DE, Lee JY, Dess RT, Narayana V, Evans C, Liss A, et al. Vessel-sparing Radiotherapy for Localised Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. Eur Urol 2017;72:617–24. 62. Desai NB, Folkert MR, Leiker A, Yan Y, Costa DN, Dess RT, et al. Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): A phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localised prostate cancer. J Clin Oncol 2020;38:TPS381–TPS381.
RkJQdWJsaXNoZXIy MTk4NDMw